Purpura thrombopénique immunologique et grossesse : état des connaissances actuelles et questions encore sans réponse

Loustau, Valentine; Pourrât, O.; Mandelbrot, Laurent; Godeau, Bertrand

doi:10.1016/j.revmed.2014.07.009

Cited by 7 publications

(2 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Due to the time to response that is about one month, dapsone cannot be considered as an emergency therapy and its efficacy should not be assessed before one to two months. Of note, dapsone can be used in children [ 22 , 37 ] and can be maintained during pregnancy [ 38 ].…”

Section: Discussionmentioning

confidence: 99%

Efficacy and safety of dapsone as second line therapy for adult immune thrombocytopenia: A retrospective study of 42 patients

et al. 2017

View full text Add to dashboard Cite

Dapsone is recommended as a second line therapy in immune thrombocytopenia (ITP), but is underused because of its potential side effects. The medical charts of 42 ITP patients treated with dapsone (100 mg/day) were retrospectively reviewed in order to assess its efficacy and safety in daily clinical practice. The overall response rate was 54.8% (n = 22, with a complete response in 38.1%) with a median time to response of 29 days (24–41 days). Patients with complete response had shorter disease duration whereas no difference was observed between responders and non-responders regarding age, sex or previous treatments received. Importantly, after dapsone withdrawal, a sustained response was observed in 5 patients, representing 12% of the whole cohort. Twenty percent of patients (n = 8) relapsed on therapy after 8.1 (6.5–13.6) months. Side effects occurred in 31% (n = 13) of patients, and required dapsone withdrawal in 22% (n = 9) or dosage reduction in 10% (n = 4) of the cases. Side effects resolved in all but one case. Overall, these data support dapsone as an interesting second line therapy in ITP, with a good safety and efficacy profile at a low cost.

show abstract

Section: Discussionmentioning

confidence: 99%

Efficacy and safety of dapsone as second line therapy for adult immune thrombocytopenia: A retrospective study of 42 patients

et al. 2017

View full text Add to dashboard Cite

show abstract

“…There is no absolute correlation between the mother's platelet count and the risk of neonatal thrombocytopenia, but this risk is even higher when the mother is thrombocytopenic and the ITP has a severe course. [18] Infectious thrombocytopenia…”

Section: Gestational Thrombocytopeniamentioning

confidence: 99%